O Shaughnessy Asset Management LLC trimmed its position in Teladoc Health, Inc. (NYSE:TDOC) by 7.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,126 shares of the health services provider’s stock after selling 333 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Teladoc Health were worth $907,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of TDOC. Tradewinds Capital Management LLC lifted its holdings in shares of Teladoc Health by 150.0% in the third quarter. Tradewinds Capital Management LLC now owns 125 shares of the health services provider’s stock valued at $27,000 after purchasing an additional 75 shares in the last quarter. Capital Advisors Ltd. LLC acquired a new stake in shares of Teladoc Health in the third quarter valued at about $30,000. Marshall Wace North America L.P. acquired a new stake in shares of Teladoc Health in the first quarter valued at about $35,000. Hoover Financial Advisors Inc. acquired a new stake in shares of Teladoc Health in the second quarter valued at about $40,000. Finally, CSat Investment Advisory L.P. acquired a new stake in shares of Teladoc Health in the second quarter valued at about $42,000. Institutional investors own 87.39% of the company’s stock.
Shares of NYSE:TDOC opened at $190.59 on Friday. Teladoc Health, Inc. has a 12-month low of $75.20 and a 12-month high of $253.00. The stock has a market cap of $27.63 billion, a PE ratio of -148.90 and a beta of 0.25. The business has a 50 day moving average of $204.88 and a 200-day moving average of $201.66. The company has a quick ratio of 11.36, a current ratio of 11.36 and a debt-to-equity ratio of 0.73.
Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, October 28th. The health services provider reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.10). The company had revenue of $288.81 million during the quarter, compared to the consensus estimate of $281.54 million. Teladoc Health had a negative net margin of 13.22% and a negative return on equity of 9.54%. Equities research analysts expect that Teladoc Health, Inc. will post -1.4 earnings per share for the current year.
In related news, insider Adam C. Vandervoort sold 2,612 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $213.10, for a total value of $556,617.20. Following the completion of the sale, the insider now directly owns 1,647 shares in the company, valued at $350,975.70. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Adam C. Vandervoort sold 2,610 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $222.46, for a total value of $580,620.60. Following the completion of the sale, the insider now owns 1,646 shares of the company’s stock, valued at $366,169.16. The disclosure for this sale can be found here. Over the last quarter, insiders sold 51,570 shares of company stock valued at $11,274,671. 3.42% of the stock is currently owned by corporate insiders.
A number of research firms recently issued reports on TDOC. Deutsche Bank Aktiengesellschaft lifted their target price on Teladoc Health from $239.00 to $244.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. JPMorgan Chase & Co. lifted their target price on Teladoc Health from $240.00 to $266.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Piper Sandler lifted their target price on Teladoc Health from $232.00 to $305.00 in a research report on Wednesday, October 28th. Stifel Nicolaus lifted their target price on Teladoc Health from $144.00 to $205.00 and gave the company a “hold” rating in a research report on Thursday, July 30th. Finally, KeyCorp boosted their price target on Teladoc Health from $240.00 to $245.00 and gave the stock an “overweight” rating in a research report on Thursday, October 29th. Eleven investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $221.33.
About Teladoc Health
Teladoc Health, Inc provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, expert medical services, behavioral health solutions, guidance and support, and platform and program services.
Recommended Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.